Evidence map›Paper›PMID 34899736›Full record

ArticleFrontiers in immunology2021

Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.

Adam D Wegman, Hengsheng Fang, Alan L Rothman, Stephen J Thomas, Timothy P Endy, Michael K McCracken, Jeffrey R Currier, Heather Friberg, Gregory D Gromowski, Adam T Waickman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026
    Review
  10. Zika immune imprint risks dengue.Nature immunology · 2026
    Article
  11. Dengue and severe dengue.Clinical microbiology reviews · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Adam D WegmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, United States.
Hengsheng FangDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, United States.
Alan L RothmanDepartment of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, United States.
Stephen J ThomasDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, United States.
Timothy P EndyDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, United States.
Michael K McCrackenViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Adam T WaickmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY, United States.
SUNY Upstate Medical University · USWalter Reed Army Institute of Research · USUniversity of Rhode Island · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue virus (DENV) is a prevalent human pathogen, infecting approximately 400 million individuals per year and causing symptomatic disease in approximately 100 million. A distinct feature of dengue is the increased risk for severe disease in some individuals with preexisting DENV-specific immunity. One proposed mechanism for this phenomenon is antibody-dependent enhancement (ADE), in which poorly-neutralizing IgG antibodies from a prior infection opsonize DENV to increase infection of F

Indexed as

Antibody-Dependent EnhancementOpsonizationAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody SpecificityChlorocebus aethiopsDengueDengue VirusHost-Pathogen InteractionsHumansImmunity, HumoralImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin GAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralImmunoglobulin AImmunoglobulin GADEantibody dependent enhancementDengueDENVIgA

Identifiers

PMID34899736
PMCPMC8654368
OpenAlexW3217584402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.